Rho-Kinase inhibitors ameliorate diclofenac-induced cardiotoxicity in chloroquine-treated adjuvant arthritic rats

Publication date: 1 August 2020Source: Life Sciences, Volume 254Author(s): Manar Hamed Arafa, Nanies Sameeh Mohammad, Hebatallah Husseini Atteia
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

Publication date: September 2020Source: Molecular Immunology, Volume 125Author(s): Shuping Zhong, Qingqing Ouyang, Dingji Zhu, Qin Huang, Jinjun Zhao, Meida Fan, Yujie Cai, Min Yang
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
AbstractObjectiveTo investigate the associations of systolic blood pressure (SBP) and diastolic blood pressure (DBP) with changes in knee cartilage composition and joint structure over 48  months, using magnetic resonance imaging (MRI) data from the Osteoarthritis Initiative (OAI).Materials and methodsA total of 1126 participants with right knee Kellgren-Lawrence (KL) score 0 –2 at baseline, no history of rheumatoid arthritis, blood pressure measurements at baseline, and cartilage T2 measurements at baseline and 48 months were selected from the OAI. Cartilage composition was assessed using MRI T2 measuremen...
Source: Skeletal Radiology - Category: Radiology Source Type: research
The objective of this study was to develop functional dark chocolate with improved organoleptic, textural and functional attributes by optimizing the ingredients levels such as flaxseed oil and honey and its further validation for quality improvement. Methods: The chocolate composition was optimized by selecting two variables including flaxseed oil (1-2.5g) and honey (10-15g) at 3 levels in central composite rotatable design (CCRD) by using Design- Expert version 11 software tool. Results: After optimization, the best-predicted formulation comprising flaxseed oil 2.37% (w/w) and honey 15% (w/w) showed best sensorial score (p
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Publication date: Available online 13 July 2020Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): B.L. Hechler, N.S. Matthews
Source: British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
Condition:   Rheumatoid Arthritis Interventions:   Biological: Blood sample;   Diagnostic Test: CRQ Sponsor:   Centre Hospitalier Universitaire de Saint Etienne Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have be...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis TREMFYA is the first and only biologic approved for the treatment of active psoriatic arthritis t... Biopharmaceuticals, FDA Janssen Pharmaceutical, Johnson &Johnson, TREMFYA, guselkumab, PsA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
HORSHAM, PA, July 14, 2020– The Janssen Pharmaceutical Companies of Johnson&Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases of childhood that often persists into adulthood and can result in significant long-term morbidity. As a long lasting chronic infla...
Source: Pediatric Rheumatology - Category: Rheumatology Authors: Tags: Research article Source Type: research
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide widely distributed in the nervous system, where it exerts strong neuroprotective effects. PACAP is also expressed in peripheral organs but its peripheral protective effects have not been summarized so far. Therefore, the aim of the present paper is to review the existing literature regarding the cytoprotective effects of PACAP in non-neuronal cell types, peripheral tissues, and organs. Among others, PACAP has widespread expression in the digestive system, where it shows protective effects in various intestinal pathologies, such as duodenal ulcer, ...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Arthritis | Biology | Cardiology | Diclofenac | Heart | Rheumatology | Voltaren